Selling these Two Over Priced Stocks

1. Glenmark Pharmaceuticals Ltd – The stock is in news after the COVID-19 medicine news. For Its Fabiflu, the market opportunity is expected to be less than Rs 1 bn. , which has less contribution to its Bottom Line. Huge Debt is nowhere to go out of balance sheet.2. Bajaj Holdings & Investment Ltd – Sudden rise in its stakes in Bajaj Finance, makes it Value rich.Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source | NSE Website | Screener.In  | Capital Line | Money Control |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext   |

Which Mall developer will Perform Well ?

Top mall developers in India are reworking their rental agreements with retailers after reopening of malls in most cities after Lockdown.

We have find that Brigade, DLF and Prestige are working on rent waivers to the Retailers, with conditions of absence of any outstanding dues by its retail partners.

While Phoenix Mills Ltd is the only developer which has worked out a three-month rent deferral programme for its tenants. It will not affect it balance sheet adversely compare to others.

Valuations : Phoenix Mills Ltd is now Trading atX1.5 of its expected earnings of FY2020 & Margin of Safety (1Yr Bond Yield: Value>1 ) is 1.1

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source | NSE Website | Screener.In  | Capital Line | Money Control |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext   |

 

Glenmark Pharmaceuticals Ltd – Drug for mild Covid patients hits market

Glenmark Pharmaceuticals Ltd  closes   at ₹ 409.10 with  a Gain    of   +0.90  %   on    19-June- 2020   with formation of  a  Green   Candle    on Daily  Price Chart.

About the Company : Glenmark Pharmaceuticals is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

The Company  is  expected to Post Sales of ₹ 10579.90Cr & Net Profit of ₹ 728.70 Cr in FY2020 and Sales of ₹11532.10 Cr & Net Profit of ₹833.80 Cr in FY2021 and Sales of ₹12540.90 Cr & Net Profit of ₹963.20  Cr in FY2022.

Valuations  : The Company is now Trading at X 0.9  of its Value. We have valued the company with its  expected Financial Year 2020 earnings  , which is now almost ~10 %  Discount   to its value & X 0.81  of its FY20201 earning with a Discount  of ~ 19%   and X 0.72  of its FY20202  earning with a Discount  of ~ 28%.

Book Value will  increase  to  ₹ 230 Per Share ( ₹ 212 in FY2019 ). It will be ₹259 in FY2021 and ₹292 in FY2022.

Why Bullish : Glenmark has introduces drug for mild Covid patients , priced at Rs 103 a pill. ( Source : Media Report )

Margin of Safety (1Yr Bond Yield: Value>1 ) is now 1.7  ,which is  attractive.  its Future Price with its FY2022 earnings is ₹ 583.

Disclaimer : We are / may going to take exposure shortly.

Join Us at   Telegram #   https://t.me/TheNiftyNext

Data Source | NSE Website | Screener.In  | Capital Line | Money Control |

The author tracks economic, behavioural and corporate tends, hoping to gauge good avenues of return based on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1 |  e-Mail : Mail@NiftyNext.Com  |  Tel +91 8802230836  |  Telegram # TheNiftyNext   |